Completed PHASE2 INTERVENTIONAL NCT00002554

Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse

RADIOLABELED BC8 (ANTI-CD45) ANTIBODY COMBINED WITH BUSULFAN AND CYCLOPHOSPHAMIDE AS TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA IN FIRST OR SECOND REMISSION OR UNTREATED FIRST RELAPSE FOLLOWED BY HLA-IDENTICAL RELATED MARROW TRANSPLANTATION

Sponsor: Fred Hutchinson Cancer Center

Conditions Leukemia

Interventions allogeneic bone marrow transplantation busulfan cyclophosphamide methotrexate radioimmunotherapy

Updated 6 times since 2017 Last updated: Mar 29, 2010 Started: Nov 30, 1993 Primary completion: Dec 31, 1999 Completion: Dec 31, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Leukemia, this trial is completed. The trial is conducted by Fred Hutchinson Cancer Center and has accumulated 6 data snapshots since 1993. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fred Hutchinson Cancer Center

Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.